OrbiMed Raises $3 Billion for Healthcare Private Equity Funds

By Daniel Okafor

OrbiMed has secured $3 billion across its healthcare private equity funds, Vietnam Investment Review reports. The figure marks one of the largest dedicated healthcare capital pools assembled by the firm to date. It signals continued investor appetite for medical assets despite a broader slowdown in private equity fundraising.

What did OrbiMed announce?

The firm closed $3 billion in commitments spanning its healthcare-focused private equity vehicles. Vietnam Investment Review, which first reported the figure, did not break the total down by individual fund, close date, or limited partner.

What the headline number does establish is scale. Three billion dollars gives OrbiMed dry powder to deploy across healthcare buyouts, growth deals, and related transactions in the sector where it has built its reputation.

Why does the number matter?

Private equity fundraising has contracted sharply since 2022. General partners across industries have struggled to reach target sizes, and many have extended timelines or cut targets. Against that backdrop, a $3 billion raise stands out.

Healthcare has remained a favored destination for institutional capital. The sector combines long demographic tailwinds with defensive revenue characteristics. Limited partners hunting durable cash flows have kept allocations open to medicine-linked strategies even as they trimmed exposure elsewhere.

For OrbiMed, the raise reinforces its position as a specialist. Firms that concentrate on one sector have generally out-raised generalists during the downturn, because investors view deep domain expertise as a way to deploy capital selectively rather than compete for inflated assets.

How will the capital be used?

The reports do not specify target companies, geographies, or deal sizes. The funds will invest across healthcare, per the announcement carried by Vietnam Investment Review.

Three billion dollars buys meaningful optionality. At typical private equity check sizes, that sum could fund dozens of mid-market control positions or a smaller number of large buyouts. Sector specialists typically spread such capital across pharmaceutical services, medical devices, and healthcare infrastructure.

What comes next?

Watch deployment speed. Raising capital in a difficult market is one test. Putting $3 billion to work at acceptable valuations is the harder one, and OrbiMed's next disclosed deals will show whether the firm sees bargains or stretched prices in healthcare assets.